Pfizer sees $1.5 billion revenue drop from COVID products next year Pfizer's 2026 R&D expenses rise due to antibody development and clinical programs Pfizer's 2025 revenue forecast revised to about ...

Pfizer reported a quarterly loss Tuesday following a large write-down, denting shares as it confirmed 2026 financial targets with lower revenues. The big US drugmaker pointed to another drop in ...

The pharmaceutical company updated its sales guidance for 2025, saying it now expects $62 billion in revenue for the year Pfizer revised its revenue expectations for 2025 and detailed its outlook for ...

Pfizer PFE stock has declined around 3% this week. On Dec. 16, the company announced its financial guidance for 2026, which fell short of investor expectations. Pfizer expects total revenues for 2026 ...

Pfizer (PFE) posted Q3 revenue of $16.65B down 5.9% as COVID products declined sharply. Paxlovid dropped 55% and Comirnaty fell 20%. Teva (TEVA) delivered its 11th consecutive quarter of growth with ...

Pfizer (PFE) shares fell in the premarket on Tuesday after the company reaffirmed its full-year outlook, indicating a revenue contraction for 2026 amid a nearly $1.5B impact attributed to some of its ...

Pfizer (PFE) looks undervalued at 8–9x forward earnings with a ~7% yield; see how Seagen, cost cuts and the pipeline could drive $36–42 upside—read now.

Pfizer PFE and AbbVie ABBV are both U.S. pharmaceutical giants with a strong leadership position in various therapeutic areas. For Pfizer, oncology sales comprise around 28% of its total revenues.

Pfizer PFE and AstraZeneca AZN are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company ...